Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell luna cancer

Current Opinion in Oncology

Volumn 18, Issue 2, 2006, Pages 144-150

  Hotta, Katsuyuki ^a   Matsuo, Keitaro ^b   Kiura, Katsuyuki ^a   Ueoka, Hiroshi ^c   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL SANYO HOSPITAL   (Japan)

Author keywords

Adjuvant chemotherapy; Cisplatin based chemotherapy; Non small cell lung cancer; UFT (tegafur and uracil)

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; UFT; VINBLASTINE; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DEATH; FATIGUE; HIGH RISK PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; POSTOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; POSTOPERATIVE CARE; PULMONARY SURGICAL PROCEDURES; RANDOMIZED CONTROLLED TRIALS;

EID: 33646683043     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000208787.91947.a2     Document Type: Review

References (35)

1. Ferlay J, Bray F, Piasani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. Version 1.0. In: IARC CancerBase No. 5. Lyon, France: IARC Press; 2001.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-1717.
3. Girling DJ, Stott H, Stephens RJ, Fox W. Fifteen-year follow-up of all patients in a study of post-operative chemotherapy of bronchial carcinoma. Br J Cancer 1985; 52:867-873.
4. Shields TW, Humphrey EW, Eastridge CE, Keehn RJ. Adjuvant cancer chemotherapy after resection of carcinoma of the lung. Cancer 1972; 40:2057-2062.
5. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641.
6. Niiranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: randomized study. J Clin Oncol 1992; 10:1927-1932.
7. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J Clin Oncol 1996; 14:1048-1054.
8. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311:899-909.
9. Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomized study on 70 patients. Chin Med J 2000; 113:617-620.
10. Mineo TC, Ambrogi V, Corsaro V, Roselli M. Postoperative adjuvant therapy for stage IB non-small cell lung cancer. Eur J Cardiothorac Surg 2001; 20:378-384.
11. Nakagawa M, Tanaka F, Tsubota N, et al. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG) - the 4th study. Ann Oncol 2005; 16:75-80. A typical example of a well conducted adjuvant UFT study in patients with resected NSCLC.
12. Tada H, Tsuchiya R, Ichinose Y, et al. Randomized study of adjuvant chemotherapy for completely resected non-small cell lung cancer: lack of prognostic significance in DNA ploidy pattern at adjuvant setting. Proc Am Soc Clin Oncol 2002; 21:313 (abstract no. 1250).
13. Endo C, Saito Y, Iwanami H, et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003; 40:181-186.
14. Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 2005; 49:85-94. A well designed study to address the role of adjuvant UFT chemotherapy.
15. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461.
16. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26:173-182. A unique randomized trial; all clinically operable patients were included in the trial, whether or not they had undergone curative resection.
17. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360. A largest randomized adjuvant trial involving 1867 patients recruited by 148 centers in 33 countries, which demonstrated a significant survival benefit of cisplatin-based chemotherapy.
18. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with Uracil-Tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713-1721. A large randomized UFT trial showing its impact on postoperative overall survival.
19. Tada H, Tsuchiya R, Ichinose Y, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004; 43:167-173.
20. Winton TL, Livingston R, Johnson D, et al. Vinorelbine and cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-2597. A well designed and large-scale randomized trial addressing the role of combination chemotherapy consisting of cisplatin plus a new agent.
21. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol 2004; 23:619 (abstract no. 7019).
22. Douillard J, Rosell R, Delena M, et al. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. Proc Am Soc Clin Oncol 2005; 24:619 (abstract no. 7013). A randomized trial comparing adjuvant cisplatin plus vinorelbine chemotherapy with surgery alone; it is of note that the median follow-up time is longer than 70 months.
23. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 1995; 13:1904-1911.
24. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005; 23:4999-5006. The first individual patient-data-based meta-analysis showing the survival benefit of adjuvant UFT monotherapy involving six trials comparing postoperative UFT monotherapy with surgery alone in 2003 patients with completely resected non-small-cell lung cancer.
25. Hotta K, Matsuo K, Ueoka H, et al. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22:3860-3867. An abstracted-data-based meta-analysis which demonstrates a benefit of adjuvant cisplatin-based chemotherapy and UFT monotherapy.
26. Sedrakyan A, Van Der Meulen J, O'Byrne K, et al. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004; 128:414-419. An abstracted-data-based meta-analysis which demonstrates a benefit of adjuvant cisplatin-based chemotherapy and UFT monotherapy; in a subgroup analysis, there was no evidence for a survival difference between Japanese and European/North American cohorts in cisplatin-based adjuvant trials.
27. Berghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49:13-23. An abstracted-data-based meta-analysis showing a benefit of neo-adjuvant chemotherapy as well as adjuvant chemotherapy.
28. Clarke MJ, Stewart LA. Obtaining individual patient data from randomized controlled trials. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care. London, UK: BMJ Publishing Group; 2001. pp. 109-121.
29. Burdett S, Stewart L, Auperin A, Pignon JP. Chemotherapy in non-small-cell lung cancer: an update of an individual patient data meta-analysis. J Clin Oncol 2005; 23:924-925. A brief report introducing an ongoing individual patient data-based meta-analysis in NSCLC patients conducted by the authors.
30. Gandara DR, Ohe Y, Kubota K, et al. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials. Proc Am Soc Clin Oncol 2004; 23:616 (abstract no. 7007).
31. Fukuoka M, Yano S, Giaccone G, et al. A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21:2237-2246.
32. Keicho N, Saijo N, Shinkai T, et al. Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 1986; 16:143-146.
33. Tanaka F, Yanagihara K, Otake Y, et al. Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer. Cancer Sci 2004; 95:371-376.
34. Baggstrom MQ, Socinski MA, Hensing TA, Poole C. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 2002; 21:306a (abstract no. 1222).
35. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1NO), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247-253.